Sugi Predict

Sugi Predict / Compounds / SCHEMBL4815073

SCHEMBL4815073

SCHEMBL4815073

O=C(O)CCc1ccc(F)c(Br)c1

nearest known ligand 0.51

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 10/20 0.51
▸ FFAR4 Q5NUL3 5/20 0.51
▸ THRA P10827 5/20 0.49
▸ THRB P10828 5/20 0.49
▸ KEAP1 Q14145 1/20 0.47
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ ESR1 P03372 1/20 0.44
▸ NR3C1 P04150 1/20 0.44
▸ PGR P06401 1/20 0.44
▸ NR3C2 P08235 1/20 0.44
▸ AR P10275 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16858444 0.90 CYP1A2 (0.53) FFAR1FFAR4THRATHRB
SCHEMBL9247568 0.86 FFAR1 (0.55) FFAR1FFAR4THRATHRBKEAP1
SCHEMBL30816271 0.86 FFAR1 (0.55) FFAR1FFAR4THRATHRBKEAP1
SCHEMBL17606043 0.84 PARP1 (0.41) FFAR1FFAR4THRATHRBESR1
SCHEMBL3093884 0.83 FFAR1 (0.53) FFAR1FFAR4THRATHRBKEAP1
SCHEMBL586063 0.83 FFAR1 (0.58) FFAR1FFAR4KEAP1CA1CA2
SCHEMBL77380 0.81 KDM4E (0.50) THRATHRBCA2
SCHEMBL23497373 0.80 PTPN1 (0.45) —
SCHEMBL29971254 0.80 PTPN1 (0.45) —
SCHEMBL3689346 0.80 CA1 (0.51) FFAR1FFAR4THRATHRBKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353817-A1 INTERLUKIN-17A INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-11-20 — — US disclosed
EP-4598933-A1 PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF Allorion Therapeutics Inc (US) 2025-08-13 — — EP disclosed
CN-119968377-A Phosphoramidate compounds and uses thereof 安锐生物医药公司 2025-05-09 — — CN disclosed
US-20250122218-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2025-04-17 — — US disclosed
EP-4476230-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2024-12-18 — — EP disclosed
US-20240317723-A1 SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2024-09-26 — — US disclosed
WO-2024078392-A1 PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) 2024-04-18 — — WO disclosed
EP-4330252-A1 SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) Ontario Institute for Cancer Research (OICR) (CA) 2024-03-06 — — EP disclosed
CN-117597340-A Substituted amino-aza-heteroaryl compounds as inhibitors of hematopoietic progenitor kinase 1 (HPK 1) 安大略省癌症研究所(OICR) 2024-02-23 — — CN disclosed
EP-3782995-B1 SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES SHANGHAI INST MATERIA MEDICA CAS (CN) 2023-11-22 — — EP disclosed
CN-101023055-B Cyclic amine derivative or salt thereof ASTELLAS PHARMA INC 2010-10-06 — — CN disclosed
US-7468371-B2 Tricyclic pyrazole kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-12-23 — — US disclosed
US-20070197594-A1 Cyclic amine derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2007-08-23 — — US disclosed
US-20070197594-A1 Cyclic amine derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2007-08-23 — — US disclosed
US-20070197594-A1 Cyclic amine derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2007-08-23 — — US disclosed
CN-101023055-A Cyclic amine derivative or salt thereof ASTELLAS PHARMA INC (JP) 2007-08-22 — — CN disclosed
EP-1795524-A1 CYCLIC AMINE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2007-06-13 — — EP disclosed
EP-1740579-A1 TRICYCLIC PYRAZOLE KINASE INHIBITORS Abbott Laboratories (US) 2007-01-10 — — EP disclosed
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors ABBVIE INC. 2006-01-19 — — US disclosed
WO-2005095387-A1 TRICYCLIC PYRAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-10-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353817-A1 INTERLUKIN-17A INHIBITORS AND USES THEREOF IL17A, IL15, IL23R FFAR1 4739/4885FFAR4 4696/4885THRA 3959/4885
US-20070197594-A1 Cyclic amine derivative or salt thereof GRIN1, PARK7, GRIN3A FFAR1 3299/4885FFAR4 4166/4885THRA 3020/4885
US-20240317723-A1 SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) DCK, CMPK1, PHKA1 FFAR1 3061/4885FFAR4 4271/4885THRA 3109/4885
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors PRKDC, PRKACA, PIK3C3 FFAR1 4001/4885FFAR4 3934/4885THRA 2170/4885
US-20250122218-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B FFAR1 1154/4885FFAR4 1101/4885THRA 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.